Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics | $10.99 | -$12.17 | -0.53% | 13.1M | $628.9M | $8.04$24.17 |
| OWLS | Obook | $10.75 | -$8.75 | -0.45% | 1.1M | $1.7B | $8.15$90 |
| ATMV | AlphaVest Acquisition Corp | $9.2 | -$4.3 | -0.32% | 180.3K | $52.0M | $8$42 |
| ATOM | Atomera | $2.9 | -$1.35 | -0.32% | 3.4M | $133.8M | $2.48$17.55 |
| RYOJ | rYojbaba | $6.5 | -$2.62 | -0.29% | 617.7K | $102.6M | $1.81$11.43 |
| OKLL | Tidal Trust II - Defiance Daily Target 2x Long Oklo ETF | $62 | -$24.34 | -0.28% | 3.5M | - | $16.09$169.96 |
| GLGG | Themes ETF Trust - Leverage Shares 2x Long Glxy Daily ETF | $28.77 | -$12.01 | -0.29% | 59.5K | - | $12.38$45.8 |
| STI | Solidion Technology | $10.69 | -$3.24 | -0.23% | 377.8K | $38.6M | $2.94$55 |
| QSU | Tidal Trust II | $14.27 | -$4.22 | -22.84% | - | - | - |
| SLMT | Brera Holdings PLC | $7.48 | -$2.13 | -22.16% | - | - | - |
Related Articles
Featured Article
Could Arcturus Therapeutics Be the Next Moderna?
Alex Carchidi|Mar 1, 2022
It's not likely, but it could still end up being a good investment.
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
Adria Cimino|Oct 15, 2021
The company disappointed last year, but things may be turning around.
Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?
Keith Speights and Brian Orelli, PhD|Mar 14, 2021
There's at least one biotech that appears to be a potential contender.
Is Arcturus Therapeutics a Buy?
Alex Carchidi|Jan 12, 2021
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
Did You Miss Out on the Chance for Big Gains from Arcturus Stock?
Adria Cimino|Jan 6, 2021
The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
Why Is Everyone Talking About Arcturus Therapeutics Stock?
Zhiyuan Sun|Jan 5, 2021
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
Markets Ease Lower as Arcturus, Blink Charging Plunge
Dan Caplinger|Dec 29, 2020
Two top performers fell back to earth on Tuesday.
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine
Eric Volkman|Dec 29, 2020
Investors obviously considered these to be underwhelming, however.
3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now
Keith Speights|Dec 20, 2020
Nothing compares to these companies.
Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks?
Adria Cimino|Dec 17, 2020
2021 may be their big year for growth and product news.
